Skip to main content

The CAROLINA trial

CAROLINA provided some much-needed clarity on the cardiovascular safety of sulfonylureas, showing that glimepiride had an equivalent cardiovascular safety to linagliptin – a dipeptidyl peptidase-4 inhibitor with an established neutral cardiovascular safety profile.

Receive weekly updates on the diabetes news that matters to you

The CAROLINA investigators will provide a comprehensive overview of their findings to date at the 55th EASD Annual Meeting (EASD 2019):

Results and implications of CAROLINA (CARdiOvascular Safety of LINAgliptin) comparing linagliptin vs glimepiride 
Thursday, September 19, 13:15–14:15, Ochoa Hall, Fira Barcelona Gran Via, Spain 
Session Chair: J. Rosenstock, USA

  1. Introduction and study background. J. Rosenstock, USA
  2. Study design and baseline characteristics. M. Espeland, USA
  3. Metabolic and weight outcomes. S .E. Kahn, USA
  4. Cardiovascular, mortality and hospitalisation outcomes. N. Marx, Germany
  5. Safety and comprehensive hypoglycaemia analyses. B. Zinman, Canada
  6. Clinical implications. D. K. McGuire, USA
  7. Commentary. P. D. Home, UK

 What our Editorial Board said: 

Sanjay Kalra tells us why he is so reassured by the findings of the CAROLINA trial pitting linagliptin against glimepiride (2:38).

Back to the EASD 2019 conference hub